Arbelic (telavancin) / Cumberland, SciClone - LARVOL DELTA

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. (PubMed, Cureus) - "Telavancin is a fairly novel antibiotic derived from vancomycin developed to combat the constant evolutionary war against bacteria. It has achieved high clinical success in its role in treating Gram-positive organisms, although like in the case of any other antibiotics, failure can arise. The purpose of this article is to describe a case in which telavancin clinically failed in treating persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in a patient while describing the cause that led to telavancin failure."

Journal • Infectious Disease

History of the Creation of a New Generation of Antibiotics of the Group of Polycyclic Glycopeptides (PubMed, Mol Biol (Mosk)) - "Over the past two decades, a series of hydrophobic glycopeptide analogues active against resistant strains of Gram-positive bacteria have been developed, three of which - oritavancin, telavancin, and dalbavancin - were approved by the US Food and Drug Administration (FDA) in 2013-2014 for the treatment of infections caused by sensitive and resistant strains of staphylococci and enterococci. The possibility of using semi-synthetic glycopeptide analogues in the fight against viral infections caused by enveloped viruses is also considered. This review outlines the main ways of chemical design in creating a new generation of glycopeptide antibiotics that overcome resistance to Gram-positive pathogens and the mechanisms of their action."

Journal • Review • Infectious Disease

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA (PRNewswire) - "Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc...and SciClone Pharmaceuticals (Holdings) Limited ('SciClone Pharmaceuticals' or 'SciClone') today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ (telavancin) injection in China. The announcement follows an agreement between the companies providing SciClone the exclusive rights to register, promote and distribute the product to patients in that country."

China approval • Infectious Disease • Pneumonia

Telavancin Use in Hospitalized Patients with Diminished Renal Clearance (ASHP 2024) - No abstract available

Clinical

Embryonic exposure to glycopeptides induces acute toxicity and developmental neurotoxicity in zebrafish (Danio rerio). (PubMed, J Hazard Mater) - "Our findings indicate that oritavancin (ORI) and telavancin (TEL) exhibit greater acute toxicity compared to vancomycin (VAN). The disruption of neurodevelopmental pathways suggests mechanisms through which these compounds influence development. These findings underscore the critical role of glycopeptide structure in toxicity and emphasize the need for further research to delineate specific affected molecular pathways, which could guide future studies and treatments for neurodevelopmental disorders."

Journal • CNS Disorders • Developmental Disorders • Infectious Disease • Psychiatry

Telavancin and Cardiac Surgery: Balancing Antimicrobial Efficacy With Coagulation Challenges. (PubMed, J Cardiothorac Vasc Anesth) - No abstract available

Journal • Surgery • Cardiovascular

Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis. (PubMed, Antibiotics (Basel)) - "This systematic review and NMA provide a new comparison framework for the clinical treatment of MRSA infection. The NMA suggests that linezolid may be the antibiotic of choice for the treatment of MRSA infections, with the ability to improve clinical and microbiological success rates despite its disadvantage in terms of adverse effects. At the same time, the combination of minocycline and rifampicin may be the most effective drug to treat MRSA-induced cSSSIs, tedizolid may be the best drug to treat MRSA-induced cSSTIs, and the combination of vancomycin and rifampicin may be the most effective treatment for MRSA-induced pneumonia. More high-quality studies are still needed in the future to further identify alternatives to vancomycin."

Journal • Retrospective data • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Telavancin Outcomes in Infections Treated with Outpatient Parenteral Antibiotic Therapy (OPAT) (IDWeek 2024) - No abstract available

Clinical • Infectious Disease

Telavancin for Refractory MRSA Bacteremia: A 10-Year Retrospective Review (IDWeek 2024) - No abstract available

Retrospective data • Review • Infectious Disease

Semisynthetic guanidino lipoglycopeptides with potent in vitro and in vivo antibacterial activity. (PubMed, Sci Transl Med) - "In recent years, semisynthetic vancomycin derivatives have been developed to overcome this problem as exemplified by the clinically used telavancin, which exhibits increased antibacterial potency but has also raised toxicity concerns. Moreover, the minimal to mild kidney effects at supratherapeutic doses of EVG7 indicate an improved therapeutic safety profile compared with vancomycin. These findings position guanidino lipoglycopeptides as candidates for further development as antibacterial agents for the treatment of clinically relevant multidrug-resistant Gram-positive infections."

Journal • Preclinical • Infectious Disease • Septic Shock

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years) (clinicaltrials.gov) - P1 | N=22 | Terminated | Sponsor: Cumberland Pharmaceuticals | Phase classification: P4 ➔ P1

Phase classification • Infectious Disease • Pediatrics

Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model. (PubMed, Antimicrob Agents Chemother) - "Further, telavancin conveyed 100% survival in this model and cleared B. anthracis from the bloodstream and organ tissues more effectively than a humanized dose of levofloxacin. Collectively, the low MICs against all strains tested and rapid bactericidal in vivo activity demonstrate that telavancin has the potential to be an effective alternative for the treatment or prophylaxis of anthrax infection."

Journal • Preclinical • Infectious Disease

Is There Another Option Than Daptomycin for Difficult-to-Treat Vancomycin-Resistant Enterococcus faecium. In-Vitro Activity of Telavancin, Dalbavancin and Oritavancin (ASM Microbe 2024) - "Daptomycin demonstrated an 82% susceptibility against 39 Enterococcus faecium VRE, followed by oritavancin with 42% susceptible rate. Dalbavancin and telavancin demonstrated an 18% and 10% susceptible respectively. For E. faecium VRE, in-vitro activity indicates daptomycin as the agent with best potency."

Preclinical • Gastrointestinal Disorder

Genomic Insights into Staphylococcus aureus Isolates Exhibiting Diminished Daptomycin Susceptibility. (PubMed, Pathogens) - "Susceptibility to daptomycin, vancomycin, linezolid, oxacillin, telavancin and dalbavancin was studied. Especially mprF and cls1 showed very high polymorphism in most isolates. Meanwhile, one isolate, MSa5, showed only single mutation in mprF (P314T)."

Journal • Infectious Disease

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With Subarachnoid Hemorrhage (clinicaltrials.gov) - P4 | N=20 | Recruiting | Sponsor: Aaron Cook | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With Subarachnoid Hemorrhage (clinicaltrials.gov) - P4 | N=20 | Not yet recruiting | Sponsor: Aaron Cook | Initiation date: Nov 2023 ➔ Feb 2024

Trial initiation date • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

Therapeutic drug monitoring of glycopeptide antimicrobials: An overview of liquid chromatography-tandem mass spectrometry methods. (PubMed, J Mass Spectrom Adv Clin Lab) - "Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is widely recognized as the gold standard for measuring small molecules, such as antibiotics. This review provides a comprehensive overview of LC-MS/MS methods available for TDM of glycopeptide antibiotics, including vancomycin, teicoplanin, dalbavancin, oritavancin, and telavancin."

Journal • Review

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections. (PubMed, Antibiotics (Basel)) - "Nosocomial central nervous system (CNS) infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing therapeutic challenge...Cefiderocol, a new siderophore extended-spectrum cephalosporin, pharmacokinetically behaves similar to established cephalosporins and at high doses will probably be a valuable addition in our therapeutic armamentarium for CNS infections. The new glycopeptides dalbavancin, telavancin, and oritavancin are highly bound to plasma proteins...The oxazolidinone tedizolid has a broader spectrum but a less suitable pharmacokinetic profile than linezolid. The halogenated tetracycline eravacycline does not reach CSF concentrations sufficient to treat colistin-resistant Gram-negative bacteria with usual intravenous dosing...An additional IVT can overcome the limited penetration of many new antibiotics into CSF. It should be considered for patients in which the CNS infection responds poorly..."

Journal • Review • CNS Disorders • Infectious Disease

Statistical distribution of micro and macro pores in acrylic bone cement- effect of amount of antibiotic content. (PubMed, J Mech Behav Biomed Mater) - "For four groups of bone cement (Palacos) specimens, containing 0.3, 0.6, 1.2 and 2.4 wt/wt% of telavancin antibiotic, seven samples per group were micro computed tomography scanned (38.97 μm voxel size)...Further analysis revealed that this effect was associated with the significantly larger frequency of micropores of 0.1-0.5 mm diameter (p < 0.05) in groups with larger antibiotic content (2.4 wt/wt% vs and 0.6 and 0.3 wt/wt%), implying that the elution of the added antibiotic produces micropores in this diameter range mainly. Based on this observation and the fatigue test results in the literature, it was suggested that micropore clusters have a detrimental effect on the mechanical properties of bone cement and play a major role in initiating fatigue cracks in highly antibiotic added specimens."

Journal • Fatigue • Orthopedics

The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia. (PubMed, Int J Antimicrob Agents) - "In our VAP model, systemic telavancin treatment reduced ETT MRSA occurrence, load, and biofilm thickness. Our findings may have a bearing on ICU patients' clinical outcomes."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With Subarachnoid Hemorrhage (clinicaltrials.gov) - P4 | N=20 | Not yet recruiting | Sponsor: Aaron Cook

New P4 trial • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2-17 years of age. (PubMed, Antimicrob Agents Chemother) - "Telavancin exposure was lower in pediatric subjects compared to adult subjects. Further studies are needed to determine the dose required in phase 3 clinical trials in pediatrics."

Journal • PK/PD data • Infectious Disease • Pediatrics

"Need one for “persistent bacteremia” too Dapto+ceftaroline vs telavancin vs something else?" (@Amit_Achhra)

Telavancin Protects Against Inhalation Anthrax Infection In The Rabbit Model (ASM Microbe 2023) - "Humanized doses of telavancin (30 mg/kg), levofloxacin (12.5 mg/kg), or saline were administered for 5 days upon PA detection. Given its long half-life in humans, dual mechanism of action which differs from currently approved anti-anthrax agents, and synergistic activity, telavancin is an ideal candidate as a medical countermeasure to inhalation anthrax infection. Further studies are warranted to determine the minimum protective dose of telavancin that would also convey 100% protection against the disease, as well as to assess the level of protection in the nonhuman primate model of anthrax infection."

Preclinical • Infectious Disease

Adaptive Laboratory Evolution of Staphylococcus aureus Resistance to Vancomycin and Daptomycin: Mutation Patterns and Cross-Resistance. (PubMed, Antibiotics (Basel)) - "Regardless of whether vancomycin or daptomycin was selected, most of the derivatives were characterized by a reduced susceptibility to daptomycin, vancomycin, telavancin, dalbavancin, and oritavancin. Resistance to vancomycin was mainly associated with mutations in the genes responsible for cell wall biosynthesis, and resistance to daptomycin was associated with mutations in the genes responsible for phospholipid biosynthesis and glycerol metabolism. However, mutations in walK and mprF were detected in derivatives selected for both antibiotics."

Journal • Infectious Disease